← Back to Screener
Esperion Therapeutics, Inc. (ESPR)
Price$3.13
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-29.87%
Price vs S&P 500 (4W)-0.31%
VGM Score63.57
Market Capitalization$805.76M
All Metrics
Book Value / Share (Quarterly)$0.32
P/TBV (Annual)82.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)74.78%
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)-23.56%
Gross Margin (TTM)68.38%
Net Profit Margin (TTM)-1.77%
EPS (TTM)$-0.06
10-Day Avg Trading Volume10.61M
EPS Excl Extra (TTM)$-0.06
Revenue Growth (5Y)12.12%
EPS (Annual)$-0.11
ROI (Annual)-486.00%
Gross Margin (Annual)67.95%
Net Profit Margin (5Y Avg)-170.77%
Cash / Share (Quarterly)$0.61
Revenue Growth QoQ (YoY)23.25%
ROA (Last FY)-4.87%
Revenue Growth TTM (YoY)61.13%
EBITD / Share (TTM)$0.34
ROE (5Y Avg)-171.90%
Operating Margin (TTM)18.12%
Cash Flow / Share (Annual)$-0.05
P/B Ratio89.53x
P/B Ratio (Quarterly)114.92x
Net Income / Employee (Annual)$-77,100
EV / Revenue (TTM)2.85x
Net Interest Coverage (TTM)0.74x
ROA (TTM)-1.81%
EV / EBITDA (TTM)15.69x
EPS Incl Extra (Annual)$-0.11
Current Ratio (Annual)1.54x
Quick Ratio (Quarterly)0.96x
3-Month Avg Trading Volume9.58M
52-Week Price Return169.83%
Revenue / Employee (TTM)$1,422,600
Tangible BV / Share (Quarterly)$0.32
P/S Ratio (Annual)2.00x
Asset Turnover (Annual)0.87x
52-Week High$4.18
Operating Margin (5Y Avg)-129.17%
EPS Excl Extra (Annual)$-0.11
CapEx CAGR (5Y)-19.71%
Tangible BV CAGR (5Y)-31.73%
26-Week Price Return-21.95%
Quick Ratio (Annual)1.02x
13-Week Price Return13.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.53x
Enterprise Value$1.19B
Revenue / Share Growth (5Y)-25.18%
Asset Turnover (TTM)1.02x
Book Value / Share Growth (5Y)-35.70%
Revenue / Employee (Annual)$1,371,200
Inventory Turnover (Annual)1.29x
Pretax Margin (Annual)-5.17%
Cash / Share (Annual)$0.68
3-Month Return Std Dev125.91%
Gross Margin (5Y Avg)71.25%
Net Income / Employee (TTM)$-25,200
ROE (Last FY)-486.00%
Net Interest Coverage (Annual)0.93x
EPS Basic Excl Extra (Annual)$-0.11
P/FCF (TTM)17.81x
Receivables Turnover (TTM)3.92x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.06
Receivables Turnover (Annual)3.66x
ROI (TTM)-59.48%
P/S Ratio (TTM)1.93x
Pretax Margin (5Y Avg)-170.68%
Revenue / Share (Annual)$1.94
Tangible BV / Share (Annual)$0.72
Forward P/E25.26x
Price vs S&P 500 (52W)145.46%
Year-to-Date Return-15.41%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.11
ROA (5Y Avg)-57.28%
Net Profit Margin (Annual)-5.63%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-2.23
EBITD / Share (Annual)$0.29
Operating Margin (Annual)14.95%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-171.72%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.06
P/TBV (Quarterly)116.21x
P/B Ratio (Annual)81.89x
Inventory Turnover (TTM)1.30x
Pretax Margin (TTM)-1.33%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)4.74%
Beta1.12x
Revenue / Share (TTM)$1.66
ROE (TTM)-59.48%
52-Week Low$0.95
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.10est. -0.03
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.93
3.93
3.93
2.55
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ESPREsperion Therapeutics, Inc. | C | B | B | $3.13 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Esperion Therapeutics develops and commercializes oral, once-daily non-statin therapies for patients with elevated LDL cholesterol. The company's portfolio includes NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, providing accessible alternatives to traditional statins. Esperion focuses on addressing the significant patient population requiring innovative lipid management solutions.